Causaly provides Covid-19 dataset to Bill and Melinda Gates' funded Global Health Drug Discovery Institute

Noelle Baquiche
Noelle Baquiche
published on March 05, 2020

At Causaly, we're honored to be supporting the 2019-nCoV Collective Research Initiative led by the Global Health Drug Discovery Institute in Beijing (GHDDI).

Launched on the 27th January in partnership with the School of Pharmaceutical Sciences (SPS) and Tsinghua University, the initiative is designed to make internal drug discovery platforms and resources available to external researchers to aid drug discovery efforts against the novel coronavirus (2019-nCoV) outbreak.

Causaly has machine-read, analyzed and mapped all existing knowledge on the corona virus genus, and supplied it to the initiative's information sharing platform, to support data collection efforts.

The main contents of the GHDDI 2019-nCoV platform include:

  1. Data mining and integration of historical drug discovery efforts against coronavirus (e.g. SARS/MERS) using AI and big data;

  2. Relevant preclinical and clinical data resources;

  3. Molecular chemical modeling and simulation data using computational tools;

  4. Latest scientific research progress on 2019-nCoV.

As part of our ongoing efforts to support Open Science and accelerate research into COVID-19, we are offering complimentary accounts for Causaly's open research dataset for all non-commercial research.

(open access is no longer available as it ended in September 2020)

Get in touch to request access, or for more information.

Leveraging AI in early stage drug discovery and due diligence: Autobahn Labs & Causaly webinar

Leveraging AI in early stage drug discovery and due diligence: Autobahn Labs & Causaly webinar

"Switching over to Causaly has been transformative" Dr. Yuxi Lin, Associate Director of Project Management at Autobahn Labs Causaly and...

Causaly raises $17 million to accelerate biomedical research and discovery of scientific breakthroughs
News

Causaly raises $17 million to accelerate biomedical research and discovery of scientific breakthroughs

Causaly, the London-based company that allows researchers and specialists to intuitively map and navigate the intricate landscape of biomedical research, has raised $17 million from investors to grow its team and expand into new markets.

The Causaly Machine-Reading Platform: From finding documents to finding evidence - ODSC

The Causaly Machine-Reading Platform: From finding documents to finding evidence - ODSC

Causaly ODSC Seminar Causaly's CTO, Artur Saudabayev, hosted an ODSC seminar on the 30th of March addressing the problem of the rapidly...

Sign up for Causaly newsletter